Honoring the Heart of Hematology Care
A look at the stories, mentors, and choices behind choosing a career in hematology — and the lasting impact these physicians can have on patients and families in the bleeding disorders community.
At a time when hematology is encountering both workforce challenges and rapid advances in care, the stories of two physicians who chose careers in hematology highlight the unique rewards of this field, the meaningful relationships they build with patients and families, and the sense of purpose that comes from helping people with bleeding disorders live fuller, more active lives.
Discovering a Career and a Community
Lauren Amos, M.D., M.S.
Lauren Amos, M.D., M.S., is a pediatric hematologist at Children’s Mercy Kansas City and an associate professor of pediatrics at the University of Missouri–Kansas City School of Medicine.
Why I Chose Hematology
I always say this was such a winding road for me. I would have never thought I’d end up a pediatric hematologist. I didn’t even know this field existed in medical school. I loved the pathophysiology of hematology, but it wasn’t until my pediatric rotations and then my time at Children’s Mercy that I really fell in love with pediatric hematology.
What ultimately drew me in was the chance to care for a baby with a bleeding disorder beginning at birth and then follow them until they graduate from college. I also get to combine those long-term relationships with families with meaningful clinical research. Once I realized I could do all of that in benign pediatric hematology, it just felt like the perfect fit.
Caring for Children, Supporting Families
My favorite part of the job is that it’s not just about the patient — it’s also about their families. I still remember the first baby I diagnosed with severe hemophilia A and being able to offer treatment that could start right away. We were giving a life-changing diagnosis, but we were also giving a treatment plan in that moment. It’s amazing to see the impact of what you do and say, and how much families remember all of that.
The Puzzle of Hematology
In our field, you have to be curious and inquisitive because a lot of times it’s a puzzle or a mystery — there’s not a specific guideline to follow. In hematology, you’re constantly weighing bleeding and thrombosis, knowing you can be wrong in either direction, or you’re working through cases where the protocols aren’t always laid out for you.
Part of what I love about hematology is that the coagulation system is incredibly complex, there’s still so much we don’t understand, and there are whole groups — such as women and girls — where we have real opportunities to do better. The art is using that curiosity, the science, and the lived experiences of patients to solve those puzzles together.
The Power of a Great Mentor
I first met Dr. Shannon Carpenter when I came to Children’s Mercy to interview for residency. We had a wonderful interview, and when I started residency and did an early elective in hematology/oncology, she pulled me into a research project.
Dr. Carpenter introduced me to other hematologists across the country, helped me build research collaborations, and encouraged me to review articles, join committees, and grow as an investigator. I truly wouldn’t be where I am today without her, and what’s amazing is how many other hematologists can say the same thing about their mentors.
"I truly wouldn’t be where I am today without her, and what’s amazing is how many other hematologists can say the same thing about their mentors."
Lauren Amos, M.D., M.S.
From Mentee to Mentor
I’m the program director for our pediatric hem/onc fellowship, so I work really closely with our trainees, and we’re fortunate to have a pediatric coagulation medicine fellowship here as well. I was actually the first fellow here to do that fourth-year coagulation fellowship, and now I’m working closely with a new coag fellow and with former fellows — one who stayed on in hemostasis and thrombosis and another who’s now running the hemophilia treatment center in Madison. It’s really special to work on research with them, get them excited, and see them make careers out of it.
A Field That Feels Like Family
I honestly feel like the hematology and bleeding disorders community is like a family. I met a peer at a workshop who is a hematologist in Dallas who’s now one of my best friends. We room together at conferences. You just build this network of people that support you, and when things are hard or you don’t know what to do, you can reach out to five people and hear back from them immediately. It’s not competitive or cutthroat. We’re all focused on trying to do what’s best for our patients.
The Shortage in Hematology
In recent years, we’ve seen a significant decrease in people wanting to go into pediatric subspecialties, hem/onc included. After COVID-19, I think a lot of people reassessed work–life balance and whether they wanted to do additional training. And if you don’t get exposure to pediatric hematology — or adult benign hematology — you don’t really see all the benefits that we have: our work–life balance, our day-to-day variety, our career opportunities, our community. Once you see it and know it, people fall in love with it, but if that exposure isn’t there, it’s hard to engage people.
You Don’t Have to Do It All at Once
When you first come out, you feel a tremendous sense of pressure to do it all — to be up there giving oral presentations at national conferences, publishing papers, doing clinical trials, and also excelling at patient care. Looking back, I can say no one can do all of that at the beginning.
Research is an evolutionary process where you start small and build on it. That’s one of the biggest lessons I try to pass on to my trainees: build a foundation, have good collaborators, and don’t feel like you have to do everything right away.
My Advice If You’re Considering Hematology
First of all, I would say go for it because I truly feel like we have the best community of providers. I’d encourage you to attend a Hemostasis and Thrombosis Research Society trainee workshop because that is where you get to listen to hematologists focused on hemostasis and thrombosis who highlight all the career opportunities you have, and then spend time in clinic with someone doing this work. Once you see a hemophilia treatment center in action — the outpatient side, the consults, the variety, and the challenges, but also how much better we can make things — it’s hard to say no.
Discovering a Career and a Community
Jennifer Davila, M.D.
Jennifer Davila, M.D., is a pediatric hematologist and co-director of the Hemophilia Treatment Center at Montefiore Einstein in the Bronx, New York, where she is also an associate professor of pediatrics at Albert Einstein College of Medicine.
Why I Chose Hematology
My mom says that in kindergarten there was a form that asked, “What do you want to be when you grow up?” and I wrote “doctor.” I don’t remember ever thinking I was going to be anything else — all roads just led to medicine.
I had immune thrombocytopenia (ITP) when I was about 12, and it lasted into college, so that was my first real introduction to being a patient with a problem that deviates from the norm. I needed a bone marrow biopsy, steroids, intravenous immunoglobulin (IVIG) — things I didn’t understand then but certainly do now. I was treated by two hematologists who were both women of color, and I remember seeing them and thinking, “Look at this great thing they’re doing. I can do that.”
I always knew I wanted to do benign hematology, not oncology. With oncology, it can feel very protocol-based: The surgeon gets the tissue, the pathologist looks at it, and you follow a regimen. In hematology, I’m the one looking under the microscope, looking at the smears and assays, making the diagnosis, and figuring out interventions that aren’t always protocol-based. I loved that aspect of it — the discovery part, the curiosity, the “cowboy” part of making it work for each patient.
Being There at Every Stage
When you’re a hematologist, you become like a family member. I've been an attending physician for 12 years now, so there are children who came to me when they were super little and are now taller than me, going off to college. Moms are sending me graduation pictures; the kids are talking to me about their girlfriends, their boyfriends, their choices.
I can look at that young man and say, “I know your target joints, where you’ve bled, what we did to treat you.” You build this incredibly deep relationship with the whole family. When it’s time to transition a patient to adult care at 21, the parents cry. They ask, “What are we going to do? Can we still call you?” And of course they do. Moms still send messages asking, “I know they have a new hematologist, but I just want to make sure you agree with this.”
From Terror to Confidence
What’s so powerful is seeing the arc that parents of children with hemophilia go through. In the beginning, when they have a brand-new baby, the parents are terrified. You’ve dropped this bomb on them — “your child has hemophilia”— and then you’re telling them, “You’re going to be able to inject them, you’re going to know what to do.” A couple of years later, you see the confidence in them. They’ve got it. You think to yourself, “See? I told you.” It’s more than just the child; it’s the entire family, and it’s a beautiful, beautiful thing.
The Value of Mentorship
When I was a resident at SUNY Downstate in Brooklyn, I met a hematologist named Dr. Scott Miller who became a huge influence on me. I always describe him as this grandpa, like a bear. He took me under his wing and talked to me like I was already a hematologist, not just a trainee. He had really high expectations of me, and that mattered — I felt like he saw something in me before I fully saw it in myself.
Years later, when I got my current position, he told me, “You have my dream job,” which was such a powerful thing to hear from someone I admired so much. And then, even later, he emailed me about a patient and basically asked, “What would you do?” It was such a full-circle moment — from being the resident who looked up to him to being the person he reached out to for advice. That’s what mentorship can do.
Filling the Gaps
Not everybody in the world has the privilege of being a doctor, and so if you are one of the privileged, you should try to take care of those patients who need you the most. You have to acknowledge where the gaps in care are — or where the future gaps in care are going to be — and try to fill those gaps so your patients don’t find themselves at some point without someone to take care of them.
We can have all the novel treatments in the world, but if you don’t have a doctor who understands how to use them to bring them to the patient, they’re just novel treatments in the ether.
"There’s something very comforting about having someone walk into the room who looks like you and who understands your language."
Jennifer Davila, M.D.
Representation Matters
I’m a first-generation American. Spanish was the first language I spoke, and I still speak it fluently. When you’re dealing with complex care, it’s very hard to navigate all of that as a person who doesn’t speak the language of the country you’re living in.
So I’ve always felt very lucky and blessed that I went into such a complex area of medicine, because now I’m able to help these patients and explain everything in their language. There’s something very comforting about having someone walk into the room who looks like you and who understands your language.
Embracing the Art — and Uncertainty — of Hematology
With hematology, you have to be somebody who doesn’t get tired of asking questions and really wants to understand the pathology of the patient and how to help them. A lot of my fellows and trainees want to have an algorithm that tells them, “If not this, then this; if not this, then that,” and hematology doesn’t work like that.
I tell them it’s OK to feel uncomfortable with not having an answer. That’s why medicine is an art. Yes, there’s science that is concrete, but there’s also a finesse to it. Part of being a hematologist is being comfortable with that finesse, and knowing there’s not always going to be an easy answer — it may take you a little time to get there.
If You’re Considering Hematology . . .
I always tell medical students: "You have to do what gets you out of bed in the morning, what puts that pep in your step.” I didn’t want to be the jack of all trades; I wanted to be the master of one, to know that thing super well and have people come to me with questions.
If you’re interested in hematology, reach out to a hematologist, go on the American Society of Hematology and Hemostasis & Thrombosis Research Society websites, ask at your hospital, and find someone to shadow. People think hematology is just iron deficiency all day, but there is so much more: pathology, interpretation, research, and these deep, longitudinal relationships with patients and families. If you’re curious and you like asking questions, it’s an incredibly fulfilling field.
The following content is provided by Genentech.
The Story Behind the Short Film Pivot Points
A tribute to hematologists
The film’s creation was driven by Genentech’s deep-rooted commitment to supporting practitioners, inspiring the next generation of hematologists, and advancing care for the bleeding disorders community.
To honor the quiet dedication, complex clinical decisions, and personal sacrifices that define a hematologist’s career, Genentech has produced a short film called Pivot Points.
The film reflects on the pivotal moments where science, patient care, and human connection meet — often long before a trainee ever writes “classical hematology” on a fellowship application.
Through a parallel narrative, Pivot Points follows a young woman’s journey into hematology alongside the story of a child with hemophilia A. Early on, the child’s world is shrouded in fog, a visual nod to the uncertainty and risk that shape life with a serious bleeding disorder. As the physician’s life unfolds — through study, training, mentorship, and key career choices — the fog gradually lifts.
The story culminates in a simple but telling image: the child playing basketball with friends.
Cultivating the Next Generation
This is a critical time for classical hematology. Even as treatment options for bleeding disorders expand, relatively few fellows ultimately choose this specialty.
Yet conditions such as hemophilia demand the kind of complex, longitudinal care that classical hematologists provide — support that spans childhood into adulthood and must continually adapt as science evolves.
Conditions such as hemophilia demand the kind of complex, longitudinal care that classical hematologists provide.
The film is also meant to serve as a beacon to inspire early career medical professionals to choose this rewarding field. The physician’s story in Pivot Points was inspired by real-world experiences shared by hematologists Jennifer Davila, M.D., and Lynn Malec, M.D., M.Sc., whose journeys into the field included early caregiving roles, powerful mentoring relationships, and defining moments at the bedside.
In February 2026, shortly before filming began, Dr. Malec passed away unexpectedly — a loss that was deeply felt by colleagues, patients, and families in the bleeding disorders community, and one that lent added poignancy and purpose to bringing Pivot Points to life.
One dedicated hematologist can shape the daily lives and long-term outcomes of many families.
Honoring the Healer, Highlighting the Therapy
Across the real-world accounts that informed Pivot Points, a consistent identity emerged: hematologists see themselves as lifelong partners in care, not just procedural experts. Their work requires mastering complex science while also standing by families through uncertainty, grief, and hope.
The film is meant to highlight the impact that the bispecific antibody HEMLIBRA (emicizumab-kxwh) has had for children and adults living with hemophilia A.
A single mentor can influence generations of hematologists and the patients they go on to serve.
One scene shows the physician sitting in front of her laptop at home, with her young daughter on her lap, watching a recording of a data presentation about HEMLIBRA — the first subcutaneous treatment option for pediatric patients with hemophilia A with or without inhibitors.
Another scene shows the physician talking with the young patient and his mother about therapy options — capturing the weight and hope of offering a therapy that can reduce bleeds and help them feel supported.
A Call to Future Hematologists
For novice physicians considering their next steps, Pivot Points offers a glimpse of how rewarding a career in classical hematology can be, not only for themselves but also for the patients they treat.
HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A with or without factor VIII inhibitors.
Important Safety Information
Boxed WARNING: THROMBOTIC MICROANGIOPATHY and THROMBOEMBOLISM
Cases of thrombotic microangiopathy and thrombotic events were reported when on average a cumulative amount of >100 U/kg/24 hours of activated prothrombin complex concentrate (aPCC) was administered for 24 hours or more to patients receiving HEMLIBRA prophylaxis. Monitor for the development of thrombotic microangiopathy and thrombotic events if aPCC is administered. Discontinue aPCC and suspend dosing of HEMLIBRA if symptoms occur.
Warnings and Precautions
Thrombotic Microangiopathy (TMA) and Thromboembolism Associated With HEMLIBRA and aPCC. In clinical trials, TMA was reported in 0.8% of patients (3/391) and thrombotic events were reported in 0.5% of patients (2/391). In patients who received at least one dose of aPCC, TMA was reported in 8.1% of patients (3/37) and thrombotic events were reported in 5.4% of patients (2/37). Patients with TMA presented with thrombocytopenia, microangiopathic hemolytic anemia, and acute kidney injury, without severe deficiencies in ADAMTS13.
Consider the benefits and risks if aPCC must be used in a patient receiving HEMLIBRA prophylaxis. Due to the long half-life of HEMLIBRA, the potential for an interaction with aPCC may persist for up to 6 months after the last dose. Monitor for the development of TMA and/or thromboembolism when administering aPCC. Immediately discontinue aPCC and interrupt HEMLIBRA prophylaxis if clinical symptoms, imaging, or laboratory findings consistent with TMA and/or thromboembolism occur, and manage as clinically indicated. Consider the benefits and risks of resuming HEMLIBRA prophylaxis following complete resolution of TMA and/or thrombotic events on a case-by-case basis.
Immunogenicity
Treatment with HEMLIBRA may induce anti-drug antibodies. Anti-emicizumab-kxwh antibodies were reported in 5.1% of patients (34/668) treated with HEMLIBRA in clinical trials. Most patients with antiemicizumab-kxwh antibodies did not experience a change in HEMLIBRA plasma concentrations or an increase in bleeding events; however, in uncommon cases (incidence <1%), the presence of neutralizing antibodies with decreasing plasma concentration may be associated with loss of efficacy.
Monitor for clinical signs of loss of efficacy (eg, increase in breakthrough bleeding events) and if observed, promptly assess the etiology and consider a change in treatment if neutralizing antiemicizumab-kxwh antibodies are suspected.
Laboratory Coagulation Test Interference
HEMLIBRA affects intrinsic pathway clotting-based laboratory tests, including activated clotting time (ACT); activated partial thromboplastin time (aPTT); and all assays based on aPTT, such as one-stage, factor VIII (FVIII) activity. Intrinsic pathway clotting-based laboratory tests should not be used. Results affected by HEMLIBRA: aPTT; Bethesda assays (clotting-based) for FVIII inhibitor titers; onestage, aPTT-based single-factor assays; aPTT-based Activated Protein C Resistance (APC- R); ACT.
Most Common Adverse Reactions
The most common adverse reactions (incidence ≥10%) are injection site reactions, headache, and arthralgia.
Drug Interactions
Clinical experience suggests that a drug interaction exists with HEMLIBRA and aPCC.
Pregnancy, Lactation, Females and Males of Reproductive Potential
Women of childbearing potential should use contraception while receiving HEMLIBRA. HEMLIBRA should be used during pregnancy only if the potential benefit for the mother outweighs the risk to the fetus. Consider developmental/health benefits, clinical need, and potential adverse effects on the breastfed child and mother.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.
Please see Brief Summary of full Prescribing Information on adjacent pages for additional Important Safety Information, including Boxed WARNING.
Experience the Journey
HemAware Spotlight is an immersive storytelling experience from HemAware, NBDF’s award-winning publication, featuring trusted stories and community voices that explore issues shaping the bleeding disorders community.
© National Bleeding Disorders Foundation
All rights reserved.